Indaptus Therapeutics, Inc. (INDP) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 315.78M USD. 52-week range 0.9200 to 5.96 USD. Data as of 2026-10-09.
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The ...